156 related articles for article (PubMed ID: 29778266)
1. Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling.
Chhatwal J; Chen Q; Aggarwal R
Infect Dis Clin North Am; 2018 Jun; 32(2):461-480. PubMed ID: 29778266
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
3. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
4. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
5. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
[TBL] [Abstract][Full Text] [Related]
6. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
Dore GJ; Hajarizadeh B
Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Kim DD; Hutton DW; Raouf AA; Salama M; Hablas A; Seifeldin IA; Soliman AS
Glob Public Health; 2015; 10(3):296-317. PubMed ID: 25469976
[TBL] [Abstract][Full Text] [Related]
9. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
10. Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.
Spaulding AC; Adee MG; Lawrence RT; Chhatwal J; von Oehsen W
Infect Dis Clin North Am; 2018 Jun; 32(2):323-345. PubMed ID: 29778259
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J; He T; Lopez-Olivo MA
Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
[TBL] [Abstract][Full Text] [Related]
12. A Guide to the Economics of Hepatitis C Virus Cure in 2017.
Linas BP; Nolen S
Infect Dis Clin North Am; 2018 Jun; 32(2):447-459. PubMed ID: 29778265
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C eradication: A long way to go.
Waheed Y
World J Gastroenterol; 2015 Nov; 21(43):12510-2. PubMed ID: 26604658
[TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of the Hepatitis C Virus Treatment Extension to Early-Stage Fibrosis Patients: Evidence from the PITER Real-World Cohort.
Ruggeri M; Coretti S; Romano F; Kondili LA; Vella S; Cicchetti A
Value Health; 2018 Jul; 21(7):783-791. PubMed ID: 30005750
[TBL] [Abstract][Full Text] [Related]
15. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.
Nguyen JT; Rich JD; Brockmann BW; Vohr F; Spaulding A; Montague BT
J Urban Health; 2015 Aug; 92(4):635-49. PubMed ID: 25828149
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.
Papatheodoridis GV; Hatzakis A; Cholongitas E; Baptista-Leite R; Baskozos I; Chhatwal J; Colombo M; Cortez-Pinto H; Craxi A; Goldberg D; Gore C; Kautz A; Lazarus JV; Mendão L; Peck-Radosavljevic M; Razavi H; Schatz E; Tözün N; van Damme P; Wedemeyer H; Yazdanpanah Y; Zuure F; Manns MP
J Viral Hepat; 2018 Mar; 25 Suppl 1():6-17. PubMed ID: 29508946
[TBL] [Abstract][Full Text] [Related]
17. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
19. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
[TBL] [Abstract][Full Text] [Related]
20. New hepatitis C therapies: the toolbox, strategies, and challenges.
Pawlotsky JM
Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
